Atopic dermatitis: improved itch symptoms with dupilumab in multitrial analysis

  • Silverberg JI & al.
  • J Am Acad Dermatol
  • 2 mar. 2020

  • de Brian Richardson, PhD
  • Clinical Essentials
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

Takeaway

  • Dupilumab is associated with improvements in pruritus symptoms in adults and adolescents with atopic dermatitis, according to results from 4 phase 3 clinical trials.

Why this matters

  • Pruritus is a major symptom of atopic dermatitis, and these results further support a beneficial role for dupilumab.

Key results

  • Dupilumab was associated with a greater improvement (least-squares mean percentage change) in daily Peak Pruritus Numerical Rating Scale score compared with placebo (P<.0001 for all style="list-style-type:circle;">
  • −47.4% vs −20.5% at 16 weeks in the SOLO 1/2 trials (adult patients, dupilumab 300 mg every 2 weeks or placebo monotherapy).
  • −47.9% vs −19.0% at 16 weeks in the AD-ADOL trial (adolescent patients, dupilumab 200 mg baseline weight
  • −57.3% vs −30.9% at 52 weeks in the CHRONOS trial (adult patients, dupilumab 300 mg every 2 weeks or placebo with concomitant topical corticosteroids).

Study design

  • 1505 patients with moderate to severe atopic dermatitis from 4 randomized controlled studies were included.
  • Funding: Sanofi; Regeneron Pharmaceuticals, Inc.

Limitations

  • Short duration (16 weeks) of monotherapy trials.